Prescription of cholinesterase inhibitors in Alzheimer's disease in France in 2000-2001: An assessment of compliance with national guidelines for diagnosis and follow-up;Prescription des anticholinestérasiques dans la maladie d'Alzheimer en France en 2000-2001: Évaluation du respect des procédures diagnostiques et de suivi

Revue Neurologique

Volumn 161, Issue 10, 2005, Pages 957-962

  Dartigues, J F ^a   Douet, C ^b   Rey, M ^c   Sencey, M ^d   Pigeon, M ^d   Sardin, F ^e   Maugendre, P ^f   Crochet, B ^c  

^a INSERM   (France)

^b ARAMSA   (France)

^c Les Mercuriales Tour Ponant   (France)

^d Caisse Nationale d'Assurance Maladie des Travailleurs Salaries   (France)

^e CANAM   (France)

^f AFSSAPS   (France)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Cross sectional study; Epidemiology; Guidelines

Indexed keywords

CHOLINESTERASE INHIBITOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; DIAGNOSTIC PROCEDURE; FEMALE; FOLLOW UP; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; PATIENT REFERRAL; PRACTICE GUIDELINE; PRESCRIPTION;

EID: 27144558608     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-3787(05)85159-8     Document Type: Article

References (11)

1. ANAES. (2000). Recommandations pratiques pour le diagnostic de maladie d'Alzheimer.
2. BERG L. (1988). Clinical Dementia Rating. Psychopharmacol Bull, 24: 637-639.
3. BOUSTANI M, PETERSON B, HANSON L et al. (2003). Screening for dementia in primary care: a summary of the evidence for the US preventive services task force. Ann Intern Med, 138: 927-937.
4. COURTNEY C, FARREL D, GRAY R et al. (2004). Long term donepezyl treatment in 565 patients with Alzheimer's Disease (AD2000): randomized double-blind trial. Lancet, 363: 2107-2215.
5. DARTIGUES JF, HELMER C, BARBERGER-GATEAU P et al. (2002). La maladie d'Alzheimer, un problème de santé publique... Une priorité Rev Neurol (Paris), 158: 311-316.
6. FOLSTEIN M, FOLSTEIN S, MCHUGH P. (1975). Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-192.
7. JONES R. (2003). Have cholinergic therapies reached their clinical boundary in Alzheimer's disease. Int J Geriatr Psychiatry, 18: S7-S13.
8. LANCTÔT K, HERRMANN N, YAU K et al. (2003). Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. Can Med Assn J, 169: 557-564.
9. LEBERT F. (2003). Inhibiteurs de la recapture de la sérotonine dans la dépression de la maladie d'Alzheimer et les autres démences. Presse Med, 32: 1181-1186.
10. RAMAROSON H, HELMER C, BARBERGER-GATEAU P et al. (2003). Prévalence de la démence et de la maladie d'Alzheimer chez les personnes de 75 ans et plus: données réactualisées de la cohorte Paquid. Rev Neurol (Paris), 159: 405-411.
11. SCARPINI E, SCHELTENS P, FELDMANN H. (2003). Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol, 2: 539-543.